Navigation Links
ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update
Date:3/24/2011

ADDISON, Texas, March 24, 2011 /PRNewswire/ -- ULURU Inc. (NYSE Amex: ULU) today announced that it has scheduled a conference call to discuss the fourth quarter and year ended 2010 financial results and to provide a general business update on Friday, April 1, 2011 at 9:00 a.m. Eastern Time.

To participate in the conference call please dial (800) 357-0498, for international callers dial (850) 429-1388 (access code 23750#) five to ten minutes prior to the initiation of the teleconference. If you are unable to listen to the live broadcast, a replay of the call will be available starting on April 1, 2011 two hours following the end of the call until April 8, 2011 at 11:59 p.m. Eastern Time. For the U.S. replay, please dial (866) 415-9493 for international callers dial (585) 419-6446 (access code 23750#). You may also access the replay of the call two hours following the end of the call until April 14, 2011 at 11:59 p.m. Eastern Time via the web by logging onto http://app.replayrecorder.com/multipoint/.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For more information about ULURU Inc., please visit www.uluruinc.com.  For more information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... ... ATA 2017 President’s Awards recipients, comprised of organizations and individuals who have ... , The ATA 2017 President’s Awards recognize individuals and organizations on the ...
(Date:4/26/2017)... ... 26, 2017 , ... Elisabete Miranda, president and CEO of ... Women magazine as one of its 2017 Enterprising Women of the Year, a ... demonstrated that they have fast-growth businesses, mentor or actively support other women and ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Miami native and ... a dentist. , “I could have never imagined back in 1991 that this journey ... Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant dentistry ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more effectively ... dairy proteins, providing direct cost savings as well as more stable pricing over ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus ... that’s the first in a new class of photodynamic cosmetics (PDC). , Allumera® ... skin, visibly reduce outward signs of aging, and minimize the appearance of pores ...
Breaking Medicine News(10 mins):